Navigation Links
ARX-01 and ARX-03 Clinical Results Presented at the 30th Annual Scientific Meeting of the American Pain Society
Date:5/18/2011

ess and advantages of its post-operative pain management approach and product candidate development.  These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceutical's product development activities and clinical trials; its ability to obtain and maintain regulatory approval of its product candidates; its ability to obtain funding for its operations; its plans to research, develop and commercialize its product candidates; its ability to attract collaborators with development, regulatory and commercialization expertise; the accuracy of AcelRx Pharmaceutical's estimates regarding expenses, capital requirements and needs for financing; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' Securities and Exchange Commission filings and reports, including its Annual Report on Form 10-K for the year ended December 31, 2010 and its Quarterly Report on From 10-Q for the three months ended March 31, 2011.  AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
2. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Consolidated Net Profit increased ... Highlights   , India Business grew by 20.87% ... to Rs. 4,886.70 Mn Rest of World (ROW) Business ... Business grew by 34.53% to Rs. 977.26 Mn Latin ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- Delivery ... once order is placed. Photo - ... a professional and in-depth market survey on Global ... reviews the basic information of Hemodialysis Machine including ... then explores global and China,s top manufacturers of ...
(Date:7/24/2014)... Scotland , July 24, 2014 Cancer patients ... gain access to state-of-the-art cancer treatment closer to home when ... next year. Varian Medical Systems (NYSE: VAR ... an order was placed in June for four TrueBeam™ medical ... systems, which offer fast and efficient radiotherapy and radiosurgery treatments, ...
Breaking Medicine Technology:Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3
... Incorporated (Nasdaq: ARAY ), the premier radiation oncology ... Euan S. Thomson, Ph.D., is scheduled to present at the ... City on Tuesday November 15, 2011 at 10:30 a.m. EST/7:30 ... the Stephens Fall Investment Conference in New York City on ...
... PARSIPPANY, N.J., Nov. 10, 2011 Columbia Laboratories, Inc. ... (NYSE: WPI ), today confirmed that the ... Food and Drug Administration (FDA) is scheduled to review ... for the reduction of risk of preterm birth in ...
Cached Medicine Technology:Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 2Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 3Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 4
(Date:7/24/2014)... CO (PRWEB) July 24, 2014 This year ... by E Light Electric and Jackson National Life, will be ... begins at 7 am, the Kids Fun Run at 7:50 ... Walk starts at 9 a.m. , “The Walk to End ... strength and dedication in the fight against this devastating disease, ...
(Date:7/24/2014)... like a medical device or surgical implant is put ... to Northwestern University,s Guillermo Ameer, most of the time, ... function. , "You will always get an inflammatory response ... in Northwestern,s McCormick School of Engineering and Applied Science ... Medicine. "A problem with commonly used plastic materials, in ...
(Date:7/24/2014)... Children,s Hospital and the University of Tennessee Health Science ... new drug shown to safely reduce the viral load ... with respiratory syncytial virus (RSV). RSV is the most ... children in the United States and worldwide. , ... Specialist John DeVincenzo, MD. DeVincenzo,s Le Bonheur lab has ...
(Date:7/24/2014)... Atlanta, GA (PRWEB) July 24, 2014 ... Act on Tuesday, President Obama cited the Atlanta ... 35 model programs from across the country ( ... training as an essential pillar of U.S. economic ... replicated nationally. , “This recognition from President Obama ...
(Date:7/24/2014)... scientists at Carnegie Mellon University, working with high-throughput ... Berkeley National Laboratory, have devised a computational method ... normal breast cells turn malignant and as they ... for analyzing how genes interact with each other ... published today by the online journal PLOS ...
Breaking Medicine News(10 mins):Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Antioxidant biomaterial promotes healing 2Health News:RSV research breakthrough to help infected children 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3
... Reporter , MONDAY, Sept. 27 (HealthDay News) -- There ... other noncarbonated beverages are associated with physical activity they ... In a study of more than 15,000 middle and ... who drank sugar-sweetened beverages, including sports drinks, were more ...
... Nearly 500 researchers, clinicians and mental health advocates ... Conference, Perinatal Mental Health Research: Harvesting the Potential, Oct. ... in Pittsburgh. The event, which focuses on women,s mental ... former First Lady Rosalynn Carter, who has been an ...
... Reinberg HealthDay Reporter , SATURDAY, Sept. 25 ... not drinking as much water as they should, and ... suggests. "Even mild dehydration can affect physiological function, ... said Samantha Heller, clinical nutrition coordinator at the Center ...
... to arrest the growth and spread of tumors, there have ... internal instruction manual. In a new study, a team ... molecule able to prevent cancer genes from "hearing" those instructions, ... published online by the journal Nature , demonstrates that ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Sept. ... about heart risks, U.S. health officials on Thursday severely ... patients with type 2 diabetes who cannot control their ... Administration officials also ordered the drug,s manufacturer, GlaxoSmithKline, to ...
... and GLG Pharma, LLC announced today that they have ... LLC has acquired the exclusive worldwide rights to a ... Researchers at Moffitt discovered several classes of STAT3 ... drugs. "Persistently activated STAT3 is a major ...
Cached Medicine News:Health News:Study Finds Teens Think Sports Drinks Are Healthy 2Health News:Study Finds Teens Think Sports Drinks Are Healthy 3Health News:U.S. Kids Drink Too Little Water: Study 2Health News:U.S. Kids Drink Too Little Water: Study 3Health News:Researchers create first molecule blocks key component of cancer genes' on-off switch 2Health News:Researchers create first molecule blocks key component of cancer genes' on-off switch 3Health News:FDA Restricts Access to Avandia 2Health News:FDA Restricts Access to Avandia 3
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... glucose monitor elevates bedside glucose testing to ... approaches the quality of central laboratory testing. ... measuring strip technology. Current glucose strips ... Multi-Well system measures and corrects hematocrit interference ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... The BreatheX is a wearable CPAP ... treatment of sleep apnea. The lightweight BreatheX ... of therapy with its built-in, rechargeable battery, ... users will no longer need to be ...
Medicine Products: